Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases

• Κύριοι συγγραφείς: Masahiro Nishibori (Συγγραφέας), Shuji Mori (Συγγραφέας), Hideo K. Takahashi (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Elsevier, 2019-05-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

High mobility group box-1 (HMGB1), a representative damage associated-molecular pattern (DAMP), has been reported to be involved in many inflammatory diseases. Several drugs are thought to have potential to control the translocation and secretion of HMGB1, or to neutralize extracellular HMGB1 by bin...